FON-2022-0484 infographic - Phase III MANIFEST-2: pelabresib + ruxolitinib vs placebo + ruxolitinib in JAK inhibitor treatment-naive myelofibrosis

  • Claire Harrison (Creator)
  • Vikas Gupta (Creator)
  • A. T. Gerds (Creator)
  • Raajit Rampal (Creator)
  • Srdan Verstovsek (Creator)
  • Moshe Talpaz (Creator)
  • Jean Jacques Kiladjian (Creator)
  • Ruben Mesa (University of Texas Health Science Center at San Antonio) (Creator)
  • Andrew Kuykendall (Creator)
  • Alessandro M. Vannucchi (Creator)
  • Francesca Palandri (Creator)
  • Sebastian Grosicki (Creator)
  • Timothy Devos (Creator)
  • Eric Jourdan (Creator)
  • Marielle J. Wondergem (Creator)
  • Haifa Kathrin Al-Ali (Creator)
  • Veronika Buxhofer-Ausch (Creator)
  • Alberto Alvarez-Larrán (Contributor)
  • Andrea Patriarca (Creator)
  • Marina Kremyanskaya (Creator)
  • Adam Mead (Creator)
  • Sanjay Akhani (Creator)
  • Yuri Sheikine (Creator)
  • Gozde Colak (Creator)
  • John Mascarenhas (Creator)

Dataset

Description

Phase III MANIFEST-2: pelabresib + ruxolitinib vs placebo + ruxolitinib in JAK inhibitor treatment-naive myelofibrosis infographic
Date made available2022
PublisherFuture Science Group

Access Dataset

Cite this